Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies
- PMID: 22039078
- DOI: 10.1158/1535-7163.MCT-11-0632
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies
Abstract
We previously found that slowly internalizing antibodies conjugated with SN-38 could be used successfully when prepared with a linker that allows approximately 50% of the IgG-bound SN-38 to dissociate in serum every 24 hours. In this study, the efficacy of SN-38 conjugates prepared with epratuzumab (rapidly internalizing) and veltuzumab (slowly internalizing), humanized anti-CD22 and anti-CD20 IgG, respectively, was examined for the treatment of B-cell malignancies. Both antibody-drug conjugates had similar nanomolar activity against a variety of human lymphoma/leukemia cell lines, but slow release of SN-38 compromised potency discrimination in vitro even against an irrelevant conjugate. When SN-38 was stably linked to the anti-CD22 conjugate, its potency was reduced 40- to 55-fold. Therefore, further studies were conducted only with the less stable, slowly dissociating linker. In vivo, similar antitumor activity was found between CD22 and CD20 antibody-drug conjugate in mice-bearing Ramos xenografts, even though Ramos expressed 15-fold more CD20 than CD22, suggesting that the internalization of the epratuzumab-SN-38 conjugate (Emab-SN-38) enhanced its activity. Emab-SN-38 was more efficacious than a nonbinding, irrelevant IgG-SN-38 conjugate in vivo, eliminating a majority of well-established Ramos xenografts at nontoxic doses. In vitro and in vivo studies showed that Emab-SN-38 could be combined with unconjugated veltuzumab for a more effective treatment. Thus, Emab-SN-38 is active in lymphoma and leukemia at doses well below toxic levels and therefore represents a new promising agent with therapeutic potential alone or combined with anti-CD20 antibody therapy.
©2011 AACR.
Similar articles
-
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).Clin Cancer Res. 2008 Oct 1;14(19):6154-60. doi: 10.1158/1078-0432.CCR-08-0404. Clin Cancer Res. 2008. PMID: 18829494
-
Antibody-_targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.Cancer Immunol Immunother. 2005 Jan;54(1):11-24. doi: 10.1007/s00262-004-0572-2. Cancer Immunol Immunother. 2005. PMID: 15693135 Free PMC article.
-
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.Clin Cancer Res. 2004 Apr 15;10(8):2868-78. doi: 10.1158/1078-0432.ccr-03-0493. Clin Cancer Res. 2004. PMID: 15102696
-
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.Mol Immunol. 2015 Oct;67(2 Pt A):107-16. doi: 10.1016/j.molimm.2014.09.014. Epub 2014 Oct 7. Mol Immunol. 2015. PMID: 25304309 Review.
-
Epratuzumab for systemic lupus erythematosus.Lupus. 2013 Apr;22(4):400-5. doi: 10.1177/0961203312469692. Lupus. 2013. PMID: 23553783 Review.
Cited by
-
Acute lymphoblastic leukemia: a comprehensive review and 2017 update.Blood Cancer J. 2017 Jun 30;7(6):e577. doi: 10.1038/bcj.2017.53. Blood Cancer J. 2017. PMID: 28665419 Free PMC article. Review.
-
Antibody-Drug Conjugates: Possibilities and Challenges.Avicenna J Med Biotechnol. 2019 Jan-Mar;11(1):3-23. Avicenna J Med Biotechnol. 2019. PMID: 30800238 Free PMC article. Review.
-
Novel CD20 monoclonal antibodies for lymphoma therapy.J Hematol Oncol. 2012 Oct 11;5:64. doi: 10.1186/1756-8722-5-64. J Hematol Oncol. 2012. PMID: 23057966 Free PMC article. Review.
-
Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.Front Immunol. 2019 Dec 20;10:2856. doi: 10.3389/fimmu.2019.02856. eCollection 2019. Front Immunol. 2019. PMID: 31921126 Free PMC article. Review.
-
_targeted drug delivery for cancer therapy: the other side of antibodies.J Hematol Oncol. 2012 Nov 9;5:70. doi: 10.1186/1756-8722-5-70. J Hematol Oncol. 2012. PMID: 23140144 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources